Trial Profile
A Phase 2 Study of Tazemetostat in Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Dec 2022
Price :
$35
*
At a glance
- Drugs Tazemetostat (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Eisai Co Ltd
- 13 Jan 2022 Status changed from active, no longer recruiting to completed.
- 27 Sep 2021 Planned End Date changed from 3 Sep 2021 to 31 Dec 2021.
- 27 Sep 2021 Planned primary completion date changed from 3 Sep 2021 to 31 Dec 2021.